Positive on pharma, like Aurobindo Pharma: Dipan Mehta

Dipan Mehta, Member at BSE & NSE told CNBC-TV18, "There is far too much uncertainty as far as Sun Pharma is concerned. I think that apart from the integration cost the basic core business is not doing as well. We are seeing revenues and margins in the US market, its key market are also underperforming and not up to our expectations. At the same time I think there is a lot more choice in other pharma companies which have delivered very good set of numbers and other companies from Gujarat with usual disclosure that we have investments and so do our clients, stocks like Torrent Pharma and Cadila Healthcare have come out with very good set of numbers.""I think Aurobindo Pharma is another company in which we have a vested interest, positive interest in it. They have also come out with decent set of numbers. Earlier it was Sun Pharma and Lupin which were really driving on account of the US sales growth rate but lot of other mid-sized companies have caught on or the kind of registrations and the product launches that they have done over past 2-3 years for a whole host of midcap pharma companies. That seems to be getting reported and playing out well in their numbers," he said."We are extremely positive on the pharma industry per se. However the mantle of the leadership or the growth performances coming through. We do feel that Sun Pharma will underperform within the pharma industry and some of the other pharma companies may do far better."